Please select an option below to help us tailor your newsletter to best suit your content interests!
A Randomized Controlled Trial of Robotic Versus Open Radical Hysterectomy for Cervical Cancer (ROCC)
VIEW TRIAL ON CLINICALTRIALS.GOVCervical cancer, cervix
Stage 2
Phase 3
Open to Enrollment
N/A
Robotic hysterecomty
N/A
Michael Ulm, MD
GOG (Gynecologic Oncology Group)
Adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma (including glassy cell)
Inclusion Criteria:
Exclusion Criteria:
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVEsophageal, Gastric, Cervical, clear cell renal cell cancer, RCC, hepatocellular carcinoma, HCC, liver cancer, HNSCC, head and neck cancer, oropharyngeal, larynx, hypopharyngeal, oral cavity, melanoma, urothelial carcinoma, bladder cancer, triple-negative breast cancer, TNBC, non-small cell lung cancer, NSCLC, colon, prostate
Stage 4
Phase 1
Open to Enrollment
>1st line
RO7502175
Anti-CCR8 antibody
Dan Vaena, MD
Genentech, Inc.
Carcinoma